Groundbreaking advancements in T-cell therapies are offering new hope for patients battling advanced HPV-related cancers. Researchers from the Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, in collaboration with the National Cancer Institute, have unveiled promising results from studies exploring the potential of innovative T-cell therapies. These findings highlight the possibility of achieving long-lasting remission and complete tumor regression in patients with advanced epithelial cancers.
The studies, led by Dr. Christian Hinrichs, Co-Director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute, were presented at the Society for Immunotherapy of Cancer (SITC 2025) Annual Meeting.
One study focused on genetically engineered T cell receptor (TCR)-T cells designed to target the HPV16 E7 oncoprotein (E7 T cells). This Phase II clinical trial included 10 patients with metastatic HPV-associated cancers, all of whom had limited treatment options. The treatment involved a conditioning regimen, a single infusion of up to 50 billion E7 T cells, and a median of three doses of adjuvant aldesleukin.
The patient group included individuals with head and neck cancer, cervical cancer, anal cancer, and esophageal cancer. The treatment was generally well-tolerated, with side effects consistent with the preparative regimen and aldesleukin.
The results were truly remarkable: 6 out of 10 patients experienced significant tumor shrinkage. Even more astonishing, two patients achieved complete tumor regression, which has remained ongoing for 11 and 12 months, respectively. Both patients had previously undergone immunotherapy and other standard treatments.
As Dr. Hinrichs noted, "Metastatic HPV-associated cancers remain difficult to treat. We found that E7-directed T cells can induce meaningful, and sometimes complete, responses in patients with limited options."
The development of this treatment was a collaborative effort between the National Cancer Institute and Rutgers Cancer Institute. The cell products for the study were manufactured on-site at Rutgers Cancer Institute, showcasing the unique capabilities of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence. This center is uniquely positioned to advance novel cell therapies through its specialized research and infrastructure.
A patient from Philadelphia, Maria, shared her experience: "Within a month, the nodules were gone, and for the first time in years, I felt free, full of energy and living the life. I can spend time with my son, do the things I love, and really enjoy life again. I'm so grateful to the team that made this possible."
In a second study, investigators reported an extraordinary finding: two patients with metastatic cervical cancer remain in complete remission a decade after receiving a single infusion of tumor-infiltrating lymphocyte (TIL) therapy. This study, conducted as part of clinical trial NCT01585428, provides compelling evidence that cellular therapy can produce long-term, potentially curative responses in epithelial cancers.
A decade after treatment, these patients showed no evidence of disease based on imaging and circulating tumor DNA analysis. The administered anti-tumor T cells underwent a temporary expansion phase, coinciding with tumor shrinkage and apparent elimination. Tumor responses have continued long after the T cell responses, suggesting that the tumors were cleared during the initial response.
Dr. Steven K. Libutti, Director of Rutgers Cancer Institute, emphasized the importance of research conducted at NCI-designated Comprehensive Cancer Centers. "Centers like ours bring together the scientific expertise, clinical resources, and collaborative environment needed to translate new discoveries from the laboratory into clinical trials, and ultimately into meaningful treatments for patients."
Sue of Washington, DC, a patient in the TIL therapy trial, shared her experience: "Now, 12 years later, I'm still cancer-free and deeply grateful to the doctors and researchers who made that possible. It's an incredible and unexpected blessing to see how my participation has led to new discoveries that have the potential to help other patients in the future."
The implications of these findings are profound. Dr. Hinrichs stated, "These studies indicate that one-time cell therapies can achieve durable responses in epithelial cancers, which historically have been more resistant to these treatments than blood cancers. The decade-long complete responses to TIL therapy give hope that these patients may be cured. The E7 T cell results that include complete responses are encouraging and support continued study of the approach."
But here's where it gets controversial... Could these therapies truly represent a cure for certain cancers? Or are there long-term side effects we don't yet understand? What are the ethical considerations surrounding these advanced treatments?
What do you think? Are you optimistic about the future of T-cell therapies? Share your thoughts in the comments below!
